Arbutus Biopharma (ABUS) said Friday new data from phase 2a trial of imdusiran followed by Barinthus Biotherapeutics' (BRNS) VTP-300 plus a low dose of nivolumab in chronic hepatitis B patients showed "promising" results.
The preliminary data showed that trial participants who received the regimen experienced increased rates of HBsAg loss compared with those who received imdusiran and VTP-300 or placebo.
The data were presented at the Liver Meeting 2024 of the American Association for the Study of Liver Diseases.
Arbutus shares were down 2% in recent trading, while those of Barinthus slid nearly 19%.
Price: 3.56, Change: -0.07, Percent Change: -2.07
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.